ATE538104T1 - Neue carbamoyloxyarylalkanoylarylpiperazinverbindung pharmazeutische zusammensetzungen, die die verbindung enthalten, und verfahren zur behandlung von schmerzen, angst und depression durch verabreichen der verbindung - Google Patents

Neue carbamoyloxyarylalkanoylarylpiperazinverbindung pharmazeutische zusammensetzungen, die die verbindung enthalten, und verfahren zur behandlung von schmerzen, angst und depression durch verabreichen der verbindung

Info

Publication number
ATE538104T1
ATE538104T1 AT08753270T AT08753270T ATE538104T1 AT E538104 T1 ATE538104 T1 AT E538104T1 AT 08753270 T AT08753270 T AT 08753270T AT 08753270 T AT08753270 T AT 08753270T AT E538104 T1 ATE538104 T1 AT E538104T1
Authority
AT
Austria
Prior art keywords
compound
anxiety
depression
treating pain
carbamoyloxyarylalkanoylarylpiperazine
Prior art date
Application number
AT08753270T
Other languages
English (en)
Inventor
Byong Sung Kwak
Hong Sik Moon
Han-Ju Yi
Young Soon Kang
Dae Joong Im
Eun Hee Chae
Sang Mi Chae
Ki Ho Lee
Original Assignee
Sk Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Holdings Co Ltd filed Critical Sk Holdings Co Ltd
Application granted granted Critical
Publication of ATE538104T1 publication Critical patent/ATE538104T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT08753270T 2007-05-14 2008-04-30 Neue carbamoyloxyarylalkanoylarylpiperazinverbindung pharmazeutische zusammensetzungen, die die verbindung enthalten, und verfahren zur behandlung von schmerzen, angst und depression durch verabreichen der verbindung ATE538104T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20070046708 2007-05-14
PCT/KR2008/002470 WO2008140198A1 (en) 2007-05-14 2008-04-30 Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound

Publications (1)

Publication Number Publication Date
ATE538104T1 true ATE538104T1 (de) 2012-01-15

Family

ID=40002366

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08753270T ATE538104T1 (de) 2007-05-14 2008-04-30 Neue carbamoyloxyarylalkanoylarylpiperazinverbindung pharmazeutische zusammensetzungen, die die verbindung enthalten, und verfahren zur behandlung von schmerzen, angst und depression durch verabreichen der verbindung

Country Status (18)

Country Link
US (3) US8815852B2 (de)
EP (2) EP2155736B1 (de)
JP (2) JP5605569B2 (de)
KR (2) KR101451799B1 (de)
CN (2) CN101679399B (de)
AT (1) ATE538104T1 (de)
AU (1) AU2008251259B2 (de)
BR (1) BRPI0811245B1 (de)
CA (2) CA2686547C (de)
DK (1) DK2155736T3 (de)
ES (2) ES2402173T3 (de)
HK (1) HK1141019A1 (de)
MX (1) MX2009012331A (de)
PL (1) PL2155736T3 (de)
PT (1) PT2155736E (de)
RU (1) RU2460731C2 (de)
WO (2) WO2008140197A1 (de)
ZA (1) ZA200907956B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815852B2 (en) * 2007-05-14 2014-08-26 Sk Biopharmaceuticals Co., Ltd. Carbamoyloxy arylalkan arylpiperazine analgesics
US8101642B2 (en) 2008-06-05 2012-01-24 Sk Biopharmaceuticals Co., Ltd. 3-substituted propanamine compounds
WO2009148290A2 (en) * 2008-06-05 2009-12-10 Sk Holdings Co., Ltd. 3-substituted propanamine compounds
US8835436B2 (en) 2009-07-10 2014-09-16 Green Cross Corporation Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same
KR101810975B1 (ko) * 2010-07-08 2017-12-20 에스케이바이오팜 주식회사 카바모일옥시 아릴알칸노일 아릴피페라진계 화합물을 포함하는 약학적 조성물
EP2864322B1 (de) 2012-06-20 2016-04-27 Novartis AG Modulatoren des komplementweges und verwendungen davon
WO2020080866A1 (ko) * 2018-10-19 2020-04-23 에스케이바이오팜 주식회사 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135756A (en) * 1964-06-02 Table ii
US3002976A (en) * 1959-10-12 1961-10-03 Paul A J Janssen 1-(2-thienyl)-omega-(4-arylpiperazine)alkanols
DE2325633A1 (de) * 1973-05-21 1974-12-12 Boehringer Sohn Ingelheim Piperazinderivate
NL8202636A (nl) * 1982-06-29 1984-01-16 Gist Brocades Nv Piperazinederivaten, werkwijzen ter bereiding daarvan en farmaceutische preparaten die deze verbindingen bevatten.
US4605655A (en) 1984-03-06 1986-08-12 Bristol-Myers Company Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives
JPS6175A (ja) * 1984-03-06 1986-01-06 ブリストル−マイア−ズ　コムパニ− 神経弛緩剤、１‐フルオロフェニルブチル‐４‐（５‐ハロ‐２‐ピリミジニル）ピペラジン誘導体
GB8909209D0 (en) 1989-04-22 1989-06-07 Wyeth John & Brother Ltd Piperazine derivatives
US5364849A (en) * 1989-04-22 1994-11-15 John Wyeth & Brother, Limited 1-[3 or 4-[1-[4-piperazinyl]]-2 arylpropionyl or butryl]-heterocyclic derivatives
FI102175B1 (fi) * 1989-04-22 1998-10-30 Wyeth John & Brother Ltd Menetelmä terapeuttisesti käyttökelpoisten piperatsiinijohdannaisten valmistamiseksi
DK0395313T3 (da) 1989-04-22 2000-06-19 American Home Prod Tertiære alkyl-funktionaliserede piperazin-derivater
GB9125900D0 (en) * 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
WO1998039324A1 (en) * 1997-03-07 1998-09-11 Takeda Chemical Industries, Ltd. 2-peperazinone-1-acetic acid derivatives and their use
ES2128266B1 (es) * 1997-07-08 2000-01-16 Vita Invest Sa Compuestos derivados de tiofeno y benzotiofeno y utilizacion y composicion correspondientes.
DE19934433A1 (de) * 1999-07-22 2001-01-25 Merck Patent Gmbh N-(Indolcarbonyl-)piperazinderivate
US20020183316A1 (en) 2000-10-27 2002-12-05 Kevin Pan Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
GB0203778D0 (en) * 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
US20040072839A1 (en) * 2002-06-14 2004-04-15 Amedeo Leonardi 1-Phenylalkylpiperazines
ITMI20021327A1 (it) * 2002-06-14 2003-12-15 Recordati Chem Pharm Nuove ossialchilpiperazine
US6770659B2 (en) * 2002-08-26 2004-08-03 Sk Corporation Benzoyl piperidine compounds
US20070208166A1 (en) * 2003-10-24 2007-09-06 Exelixis, Inc. Tao Kinase Modulators And Method Of Use
WO2005058823A1 (ja) * 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
PE20060426A1 (es) * 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
CN101501008B (zh) 2006-08-17 2011-12-07 弗·哈夫曼-拉罗切有限公司 芳基哌嗪衍生物及其用途
US8815852B2 (en) * 2007-05-14 2014-08-26 Sk Biopharmaceuticals Co., Ltd. Carbamoyloxy arylalkan arylpiperazine analgesics
KR101810975B1 (ko) * 2010-07-08 2017-12-20 에스케이바이오팜 주식회사 카바모일옥시 아릴알칸노일 아릴피페라진계 화합물을 포함하는 약학적 조성물

Also Published As

Publication number Publication date
US20120095007A2 (en) 2012-04-19
EP2155736A4 (de) 2010-11-10
JP2010526871A (ja) 2010-08-05
CA2686926C (en) 2016-01-05
PT2155736E (pt) 2012-03-28
PL2155736T3 (pl) 2012-09-28
EP2150550A4 (de) 2010-11-10
DK2155736T3 (da) 2012-03-12
EP2150550B1 (de) 2013-02-27
EP2155736B1 (de) 2011-12-21
US20140088095A1 (en) 2014-03-27
CA2686926A1 (en) 2008-11-20
EP2150550A1 (de) 2010-02-10
ES2402173T3 (es) 2013-04-29
KR101468553B1 (ko) 2014-12-09
CA2686547C (en) 2015-12-08
JP2010526870A (ja) 2010-08-05
CN101679400B (zh) 2013-04-17
KR20080100765A (ko) 2008-11-19
US20110195963A1 (en) 2011-08-11
AU2008251259B2 (en) 2013-02-14
US8901116B2 (en) 2014-12-02
US20100160331A1 (en) 2010-06-24
MX2009012331A (es) 2010-02-10
RU2009146132A (ru) 2011-06-20
EP2155736A1 (de) 2010-02-24
ZA200907956B (en) 2011-01-26
WO2008140198A1 (en) 2008-11-20
CA2686547A1 (en) 2008-11-20
JP5605569B2 (ja) 2014-10-15
CN101679399A (zh) 2010-03-24
ES2379848T3 (es) 2012-05-04
KR20080100766A (ko) 2008-11-19
WO2008140197A1 (en) 2008-11-20
US8541409B2 (en) 2013-09-24
US8815852B2 (en) 2014-08-26
CN101679399B (zh) 2013-11-06
RU2460731C2 (ru) 2012-09-10
JP5387917B2 (ja) 2014-01-15
BRPI0811245B1 (pt) 2021-05-25
BRPI0811245A2 (pt) 2014-11-04
CN101679400A (zh) 2010-03-24
HK1141019A1 (en) 2010-10-29
KR101451799B1 (ko) 2014-10-16
AU2008251259A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
ATE538104T1 (de) Neue carbamoyloxyarylalkanoylarylpiperazinverbindung pharmazeutische zusammensetzungen, die die verbindung enthalten, und verfahren zur behandlung von schmerzen, angst und depression durch verabreichen der verbindung
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
RU2003132687A (ru) Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv
EA200971041A1 (ru) Новые пептидные ингибиторы репликации вируса гепатита с
UA101601C2 (uk) Інгібітори амідогідролази жирних кислот
ATE268179T1 (de) Verwendung von substituierten imidazo (1,2- a)pyridin-, -pyrimidin- und -pyrazin-3-yl-amin- derivaten zur herstellung von medikamenten zur nos-inhibierung
EA200800783A1 (ru) Композиция тразодона для введения один раз в день
ATE441632T1 (de) Gesättigte und ungesättigte 3-pyridyl- benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
EA201071040A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40
PE20060176A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparacion, y su empleo como medicamentos
TW200806299A (en) Treatment of pain
AR060974A1 (es) Compuesto de 4-piridinona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende, proceso para su preparacion y proceso para la preparacion de un compuesto intermediario de utilidad en el anterior
NO20071058L (no) Risedronatsammensetninger og deres fremgangsmater for anvendelse
MX2007006082A (es) Tetrahidroisoquinolinas aril- y heteroaril-sustituidas, y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina.
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
ATE373474T1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
EA200802020A1 (ru) Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1
EA200702072A1 (ru) Фенилсодержащие n-ацильные производные аминов и аминокислот, способ их получения, фармацевтическая композиция и их применение
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
HK1079526A1 (en) A novel pyrazine compound and its use in the manufacture of a medicament for treating diseases related to serotonin
ATE353645T1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
GEP20043304B (en) Thienodibenzoazulene Compounds as Tumor Necrosis Factor Inhibitors
DE602004002394D1 (de) (3-ä3-'(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINOÜ-PROPOXYü-PHENYL)-ESSIGSÄURE UND VERWANDTE VERBINDUNGEN ALS MODULATOREN VON PPARS UND VERFAHREN ZUR BEHANDLUNG VON STOFFWECHSELSTÖRUNGEN
DE602004015406D1 (de) Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen
RU2005130002A (ru) Производные 3-метил-2-(2-фенилоксазол-4-илметокси)циклогексанкарбониламино)масляной кислоты и родственные соединения в качестве модуляторов ppar для лечения диабета типа 2 и атеросклероза